The KNCV section Medicinal Chemistry organizes a morning and afternoon session during FIGON-DMD. The program of this session will be interdisciplinary and address interesting research topics, ranging from synthesis of bioactive molecules to set up of in vitro assays to test compounds. Therefore, this session is accessible to a wide public. Between lectures, there will be time for questions and discussion to make this an inspiring meeting for both presenters and audience. Presentations will be given by young researchers from academia (PhD students and PostDocs) and industry (SME). The PhD student who gives the best presentation will have the chance to represent the Dutch Medicinal Chemistry community at the European Federation for Medicinal Chemistry (EFMC) Young Medicinal Chemist Symposium.
About the Section of Pharmacochemistry
The Section of Pharmacochemistry has been a section of the Royal Dutch Chemistry Association (KNCV) since 28 August 1970. It was founded in Maastricht during a national symposium on the subject of "Rational Design of Bio-active Compounds".
Field of expertise - The section of pharmacokemistry of the KNCV is the Dutch meeting place for anyone who deals with pharmacochemical research. Pharmacochemistry * is a highly multidisciplinary discipline whose main objective is to develop biologically active compounds. This applies in particular to the development of medicines. In order to get a new drug pharmaco chemists are involved in designing, synthesis, isolation, structural retardation and pharmacological / toxicological testing of biologically active compounds as well as research into the proteins and other targets that affect the active substances. The interpretation of molecular-level biological activities and the establishment of structure-activity relationships (SAR) play an important role.
Members - Due to the multidisciplinary nature of the pharmacochemistry, besides Dutch pharmacokemics, pharmacologists, molecular biologists, pharmacists, analytical chemists, organic chemists, biochemists, molecular modeling experts, doctors and toxicologists are members of the Pharmacochemistry.
* See the EFMC Position Paper on Medicinal Chemistry at http://www.efmc.info
The session about Receptor Pharmacology and Signal Transduction is reserved on Tuesday during these days. KNCV section Pharmacochemistry will organize this session in collaboration with the NVF and NVKFB. For this session an invited lecturer is planned even as speakers for the abstracts submitted.
When and how a cell knows which signal is essential to adapt to changing environments? This question represents the basis of receptor pharmacology and signal transduction research. Our session includes research on understanding how a cell integrates sensing to signaling and transduces these signals from the plasma membrane to mitochondria, endoplasmic reticulum and to the nucleus. It consist of a complex series of intracellular cascades mediated by modulation of G-protein-coupled receptors, phospholipids, calcium, or protein phosphorylation. Understanding these processes might provide a detailed roadmap of how cells work, and ultimately of human physiology and pathologies. Therefore, this knowledge is essential for the development of novel therapeutic strategies to treat cancer, cardiovascular, neurological and metabolic disorders. These research questions fit well in the theme of the FIGON Drugs and Microbes, since it links the external signals to potential therapies against human diseases.
Prof. dr. Martine Smit is professor at the division of Medicinal Chemistry at the Vrije Universiteit Amsterdam. Her research focuses on unraveling and modulating (e.g. nanobodies) signaling networks activated by (oncogenic) G protein-coupled receptors, with a specific interest in (viral) chemokine receptors. She is chairing this session on behalf of the Dutch Pharmacological Society and section KNCV-Farmacochemie.
Dr. Amalia Dolga is an Assistant Professor and a Rosalind Franklin Fellow at the University of Groningen, Department of Molecular Pharmacology, Groningen Research Institute of Pharmacy. Her lab investigates molecular mechanisms of neurodegeneration (Alzheimer's and Parkinson's disease), with a focus on potassium channel modulation, mitochondrial metabolism and inflammation. She is co-chairing this session on behalf of the Dutch Pharmaceutical Society."
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly